Erector Spinae Plane (ESP) Block for Renal Colic
Can Erector Spinae Plane (ESP) Block Better Relieve Acute Renal Colic Pain Than Standard of Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Secko, MD
- Phone Number: 631-624-3849
- Email: Michael.secko@stonybrookmedicine.edu
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- StonyBrook University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 65 years old
- ASA Level I and II
- flank pain concerning for renal colic in ED
Exclusion Criteria:
- pregnant women
- subjects unable to appreciate ESP block landmarks under ultrasound
- skin infection over needle site insertion
- Allergy to local anesthesia (lidocaine/Ropivacaine)
- bleeding disorders
- serious cardiac, lung, liver or kidney dysfunction
- history of spine surgery
- history of spinal infection
- history of epidural injection within 6 months
- acute exacerbation of serious mental disease
- unable to consent
- unable to communicate pain level
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: ESP Nerve Block for Renal colic
On top of receiving standard of care, At T8 nerve level, with ultrasound guidance to bathe the nerve
|
Local anesthesia injected under ultrasound guidance
|
|
Active Comparator: Standard of care
Whatever medications the clinician normally treats renal colic with
|
Whatever the ED clinicians normally give for renal colic pain
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline Pain before intervention
Time Frame: Before the ESP Block
|
Using the Visual Analog Scale for Pain Assessment Tool with 0 meaning "No pain" and 10 meaning "Unbearable Pain"
|
Before the ESP Block
|
|
Pain score at 10 minutes
Time Frame: 10 minutes after the ESP Block
|
Using the Visual Analog Scale for Pain Assessment Tool with 0 meaning "No pain" and 10 meaning "Unbearable Pain"
|
10 minutes after the ESP Block
|
|
Pain score at 20 minutes
Time Frame: 20 minutes after ESP Block
|
Using the Visual Analog Scale for Pain Assessment Tool with 0 meaning "No pain" and 10 meaning "Unbearable Pain"
|
20 minutes after ESP Block
|
|
Pain score at 40 minutes
Time Frame: 40 minutes after ESP Block
|
Using the Visual Analog Scale for Pain Assessment Tool with 0 meaning "No pain" and 10 meaning "Unbearable Pain
|
40 minutes after ESP Block
|
|
Pain score at 60 minutes
Time Frame: 60 minutes after ESP Block
|
Using the Visual Analog Scale for Pain Assessment Tool with 0 meaning "No pain" and 10 meaning "Unbearable Pain
|
60 minutes after ESP Block
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Need for extra opiates
Time Frame: Starting from time 0 after the ESP Block intervention completed till discharge or urology intervention
|
Record how much opioids patients receives starting after the ESP Block for both the "standard of care" patients and the ESP Block group
|
Starting from time 0 after the ESP Block intervention completed till discharge or urology intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael Secko, MD, StonyBrook University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB2021-00518
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.